135
Participants
Start Date
April 20, 2015
Primary Completion Date
May 15, 2017
Study Completion Date
May 15, 2017
Aldoxorubicin
230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
Topotecan
1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
Penn State Hershey Cancer Institute, Hershey
Northwest Georgia Oncology Centers, P.C., Marietta
Sarah Cannon Research Institute, Nashville
Tennessee Oncology, Chattanooga
Tennessee Cancer Specialists, Knoxville
James Graham Brown Cancer Center, Louisville
Oncology Hermatology Care, Inc., Cincinnati
Cedars-Sinai Medical Center, Los Angeles
City of Hope Medical Group, Pasadena
Northwest CCOP Kaiser Permanente, Portland
Cancer Specialists of North Florida-Fleming Island, Fleming Island
Koranyi National Institute of TBC and Pulmonologyhhy, Budapest
Koranyi National Institute of TBC and Pulmonology, Budapest
University of Debrecen, Medical and Health Science Center, Department of Pulmonology, Debrecen
Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Pulmonology, Nyíregyháza
Medical Center of the University of Pecs, 1st Department of Internal Medicine, Pécs
Hetenyi Geza Hospital, Szolnok
Hospital General Universitario de Alicante, Alicante
Hospital Clinic i Provincial de Barcelona, Barcelona
Hospital Universitario Quiron-Dexeus (IOR), Barcelona
University Hospital Vall d'Hebron, Barcelona
Hospital Universitario Lucus Augusti, Lugo
General University Hospital Gregorio Maranon, Madrid
Hospital Puerta de Hierro, Madrid
University Hospital Foundation Jimenez Diaz, Madrid
University Hospital La Paz, Madrid
Hospital Regional Universitario, Málaga
University Hospital Virgen de Valme, Seville
CHU Xeral, Vigo
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY